当前位置: 首页 >> 检索结果
570. Serious Asthma Events with Budesonide plus Formoterol vs. Budesonide Alone.
作者: Stephen P Peters.;Eugene R Bleecker.;Giorgio W Canonica.;Yong B Park.;Ricardo Ramirez.;Sally Hollis.;Harald Fjallbrant.;Carin Jorup.;Ubaldo J Martin.
来源: N Engl J Med. 2016年375卷9期850-60页
Concerns remain about the safety of adding long-acting β2-agonists to inhaled glucocorticoids for the treatment of asthma. In a postmarketing safety study mandated by the Food and Drug Administration, we evaluated whether the addition of formoterol to budesonide maintenance therapy increased the risk of serious asthma-related events in patients with asthma.
571. Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma.
作者: David A Stempel.;Stanley J Szefler.;Søren Pedersen.;Robert S Zeiger.;Anne M Yeakey.;Laurie A Lee.;Andrew H Liu.;Herman Mitchell.;Kenneth M Kral.;Ibrahim H Raphiou.;Barbara A Prillaman.;Kathleen S Buaron.;Suyong Yun Kirby.;Steven J Pascoe.; .
来源: N Engl J Med. 2016年375卷9期840-9页
Long-acting beta-agonists (LABAs) have been shown to increase the risk of asthma-related death among adults and the risk of asthma-related hospitalization among children. It is unknown whether the concomitant use of inhaled glucocorticoids with LABAs mitigates those risks. This trial prospectively evaluated the safety of the LABA salmeterol, added to fluticasone propionate, in a fixed-dose combination in children.
576. Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.
作者: Stuart J Connolly.;Truman J Milling.;John W Eikelboom.;C Michael Gibson.;John T Curnutte.;Alex Gold.;Michele D Bronson.;Genmin Lu.;Pamela B Conley.;Peter Verhamme.;Jeannot Schmidt.;Saskia Middeldorp.;Alexander T Cohen.;Jan Beyer-Westendorf.;Pierre Albaladejo.;Jose Lopez-Sendon.;Shelly Goodman.;Janet Leeds.;Brian L Wiens.;Deborah M Siegal.;Elena Zotova.;Brandi Meeks.;Juliet Nakamya.;W Ting Lim.;Mark Crowther.; .
来源: N Engl J Med. 2016年375卷12期1131-41页
Andexanet alfa (andexanet) is a recombinant modified human factor Xa decoy protein that has been shown to reverse the inhibition of factor Xa in healthy volunteers.
578. Drug-Eluting or Bare-Metal Stents for Coronary Artery Disease.
作者: Kaare H Bønaa.;Jan Mannsverk.;Rune Wiseth.;Lars Aaberge.;Yngvar Myreng.;Ottar Nygård.;Dennis W Nilsen.;Nils-Einar Kløw.;Michael Uchto.;Thor Trovik.;Bjørn Bendz.;Sindre Stavnes.;Reidar Bjørnerheim.;Alf-Inge Larsen.;Morten Slette.;Terje Steigen.;Ole J Jakobsen.;Øyvind Bleie.;Eigil Fossum.;Tove A Hanssen.;Øystein Dahl-Eriksen.;Inger Njølstad.;Knut Rasmussen.;Tom Wilsgaard.;Jan E Nordrehaug.; .
来源: N Engl J Med. 2016年375卷13期1242-52页
Limited data are available on the long-term effects of contemporary drug-eluting stents versus contemporary bare-metal stents on rates of death, myocardial infarction, repeat revascularization, and stent thrombosis and on quality of life.
|